2015 Fiscal Year Final Research Report
A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease
| Project/Area Number |
25460963
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MOCHIZUKI Shinichi 北九州市立大学, 国際環境工学部, 講師 (10520702)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 炎症性腸疾患 / ドラッグデリバリーシステム / アンチセンス |
|---|
| Outline of Final Research Achievements |
Antisense technologies for the inhibition of gene expression provide an effective strategy in inflammatory bowel disease (IBD). We have developed a delivery system for antisense using schizophyllan (SPG), a polysaccharide that belongs to the β- glucan family. This system has several advantages enabling the effective suppression of targeted RNA or DNA: SPG complex is stable and effectively taken up into macrophages through Dectin-1.
TNF-alpha mainly produced by macrophages has been shown to have a pathogenetic role in IBD. The effect of antisense TNF-alpha/SPG complex to intestinal macrophages of DSS colitis was shown the increase of uptake into macrophages and the suppression of TNF-alpha. The rectal administration of antisense TNF-alpha/SPG complex effectively suppressed TNF-alpha production and significantly ameliorated intestinal inflammation.
Our result demonstrated the usefulness of local administered antisense/SPG as new therapeutic approach in IBD.
|
| Free Research Field |
炎症性腸疾患
|
